Become A Featured Company

CURE Pharma Brings Innovative Drug Delivery to Cannabis & Beyond

Ryan Allway

July 7th, 2017

News, Top Story

Drug delivery systems have become increasingly important in the pharmaceutical industry as companies look to beat generic competition. At the same time, the cannabis industry has sought out alternative delivery systems to smoked cannabis that can more effectively deliver cannabinoid compounds to treat a growing range of medical conditions. Investors may want to take a look at companies operating in this innovative industry subset.

In this article, we will look at CURE Pharmaceutical’s (OTCQB: CURR) innovative delivery system and what it means for the cannabis industry.

Why Drug Delivery?

Drug delivery is an important problem facing the pharmaceutical industry. While pills and capsules have become commonplace, these delivery mechanisms suffer from issues like the inability to target specific parts of the body, slow uptake, and non-compliance. New drug delivery systems use everything from inhalation to intravenous injection to absorption through the skin, with to goal of quickly and effectively solving these problems and better targeting disease.

Delivery mechanisms may also play a bigger role in medicine moving forward. For instance, they may help pharmaceutical companies extend the life of patents by reformulating active ingredients in ways that improve their safety or efficacy profiles compared to generics. Delivery systems may also be used alongside advanced imaging technologies to diagnose and treat diseases in a single step through a relatively new strategy called “theranostics”.

CURE Pharmaceutical is a fully-integrated speciality pharmaceutical company focused on disruptive proprietary drug delivery technologies for a broad range of molecules serving the biopharmaceutical, veterinarian, medical foods, and pharmaceutical cannabis markets. The company’s mission is to deliver proven drugs in a fast and efficient manner to improve patient quality of life across a wide range of potential indications.

Transdermal Technology

CURE Pharmaceutical’s innovative transdermal drug delivery platform is designed to deliver therapeutically-effective amounts of a drug across a patient’s skin. By using vasodilators and proprietary encapsulants, the technology opens the pores sufficiently to enable the passive transport of active ingredients and solvents across the epidermis layer of the skin and into the dermis and subdermal tissue. The idea is to maximize both patient compliance and bioavailability.

“Transdermal drug delivery is one of our proprietary drug delivery technologies that helps us support our mission to improve people’s lives by refining how medicines and health products are delivered and experienced,” says CEO Rob Davidson. “We expect to experience increased demand for our transdermal products as consumers and the healthcare industry increasingly turn to drug delivery methods that result in improved drug delivery and medication compliance.”

Transdermal patches are already widely used across several industries, including the multi-billion dollar market for smoking cessation products and pain management. Improved bioavailability could help make these products even more effective, while potentially expanding the scope of products that could leverage these kinds of delivery mechanisms. The market for these delivery systems is projected to grow 11.6% to reach $95.57 billion by 2025.

Oral Thin Film

CURE Pharmaceutical’s CureFilm™ is the most advanced oral thin film on the market with the potential to disrupt multiple industries by leveraging cannabinoids to treat pain, neuropathy, cancer, psychiatric disorders, autoimmune disease, Parkinson’s disease, and sleep disorders. Recently, the company partnered with a contract research organization to conduct a transdermal absorption study to prove the speed, variability, duration, and functionality of the delivery matrix.

The technology has several key advantages over other delivery mechanisms:

With the cannabis industry projected to exceed $50 billion by 2026, according to Cowen & Co., the company could see tremendous demand for this innovative delivery technology.

Looking Ahead

CURE Pharmaceutical (OTCQB: CURR) represents a compelling opportunity in the pharmaceutical and cannabis industries. With innovative delivery systems in development, the company is well positioned to build out its CureFilm™ products, while expanding into other areas through partnership opportunities. Investors may want to keep an eye on the company given its vast potential and modest market capitalization as it moves forward with its commercialization plans.

For more information, visit the company’s website at www.curepharmaceutical.com.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading